Renaissance Technologies’s Pasithea Therapeutics KTTA Stock Holding History

Renaissance Technologies’s Portfolio KTTA Stock Details KTTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$69.3K	Buy	+93,399	New	+$78.1K	﹤0.01%	3074
2025 Q4	–	Sell	-30,700	Closed	-$22.5K	–	3522
2025 Q3	$22.5K	Buy	+30,700	New	+$22.4K	﹤0.01%	3416
2024 Q1	–	Sell	-1,625	Closed	-$12K	–	3907
2023 Q4	$12K	Buy	1,625 +82	+5%	+$608	﹤0.01%	3626
2023 Q3	$15K	Sell	1,543 -193	-11%	-$2.11K	﹤0.01%	3554
2023 Q2	$17K	Buy	1,736 +186	+12%	+$1.5K	﹤0.01%	3791
2023 Q1	$12K	Buy	+1,550	New	+$17.5K	﹤0.01%	3873

Other funds holding KTTA

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $273M AUM

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

PAP

Persistent Asset Partners Hong Kong $268M AUM 158.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies's KTTA Position: Q1 2026 in Review

Renaissance Technologies opened a new position in Pasithea Therapeutics (KTTA) in Q1 2026: 93,399 shares worth $69.3K. The stake represents ﹤0.01% of the portfolio and ranks #3074 among its holdings. This is a return to the name: Renaissance Technologies previously reported a position in KTTA as recently as Q3 2025.

Renaissance Technologies first reported a position in KTTA in Q1 2023 and has held it in 6 quarters since. 21 funds tracked by Wall St. Rank hold KTTA as of Q1 2026.

Renaissance Technologies held 93,399 shares of Pasithea Therapeutics worth $69.3K as of Q1 2026.
Pasithea Therapeutics was a new Renaissance Technologies position in Q1 2026.
Pasithea Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2026, its #3074 holding.
Renaissance Technologies first reported a position in Pasithea Therapeutics in Q1 2023 and has held it in 6 quarters since.
21 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.